Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

European Medicines Agency Recommends Lifting Of Supply And Treatment Restrictions For Neupro
The European Medicines Agency has recommended that the supply and treatment restrictions for Neupro (rotigotine transdermal patch), from Schwarz Pharma Ltd, be lifted. Once this recommendation is endorsed by the European Commission, the ban on prescribing Neupro to patients not yet taking the medicine will be reversed. Doctors in the European Union will then be able to prescribe Neupro to all patients in accordance with the approved product information and prescriptions will no longer be limited to one month.
generic viagra online
Interactive Medica Launches Pharmaceutical Key Account Management SaaS Solution
Interactive Medica, the leading Pharma SaaS provider, today launches IM Strategic Selling, a new Software as a Service (SaaS) solution that enables promotional teams, managers and executives to identify, collaborate, plan and manage goals, strategies and activities for current and potential Key Accounts.
News of the day
Novel Clinical Practice Guideline Manual Released By ENT Society
The world"s largest ear, nose, and throat professional medical association, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS), has released a manual detailing best practices for the creation of new clinical practice guidelines. The manual is published as a supplement to the June issue of Otolaryngology - Head and Neck Surgery.
Sexual Health

POZEN Receives Decision From AstraZeneca To File PN 400 NDA

POZEN Inc. (NASDAQ: POZN) reported that AstraZeneca has made the decision to have POZEN file the New Drug Application (NDA) for PN 400 with the United States Food and Drug Administration (FDA). POZEN continues to target a mid-2009 NDA filing and expects to receive a milestone payment of $10 million when the NDA is formally accepted for submission by the FDA. The license agreement executed with AstraZeneca in August 2006 established a Phase III clinical development program for PN 400, an investigational compound, that combines the pain reliever naproxen (an NSAID) with esomeprazole magnesium, a proton pump inhibitor (PPI), to support a potential indication for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers. POZEN Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009